IGI Laboratories (IG) 4.12 $IG
IGI Laboratories, Inc. Appoints Damian Finio to Board of Directors
PR Newswire - Wed Apr 02, 8:00AM CDT
IGI Laboratories, Inc. (NYSE MKT: IG), a New Jersey-based generic topical pharmaceutical company, today announced that it has appointed Damian Finio to its Board of Directors. Mr. Finio will serve as the new Chairman of the Company's Audit Committee. The Company had announced on March 31, 2014, that Michael Hemric, a Director of the Company has resigned effective April 1, 2014, and Joyce Erony, the Company's chairperson and director, had decided not to run for re-election at the Company's annual meeting on May 27, 2014.
IGI Laboratories To Present At Needham & Company's 13th Annual Healthcare Conference On April 8, 2014
PR Newswire - Mon Mar 31, 7:00AM CDT
IGI Laboratories, Inc. (NYSE Amex: IG), a New Jersey based topical generic pharmaceutical company, will be presenting at the Needham & Company's 13th Annual Healthcare Conference. The Conference will take place on April 8-9, 2014 at the Westin Grand Central Hotel in New York City.
IGI Laboratories (IG) Catches Eye: Stock Up 10.0% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 19, 8:25AM CDT
IGI Laboratories was a big mover last session, with shares rising almost 10% on the day.
IGI Laboratories wins first ANDA approval for lidocaine hydrochloride USP 4% topical solution
M2 - Thu Mar 13, 4:06AM CDT
Pharmaceutical company IGI Laboratories (NYSE MKT:IG) said on Wednesday that it has received the US Food and Drug Administration's (FDA) approval for the abbreviated new drug application (ANDA) of lidocaine hydrochloride USP 4% topical solution.
IGI Laboratories, Inc. Announces First ANDA Approval
PR Newswire - Wed Mar 12, 11:08AM CDT
IGI Laboratories, Inc. (NYSE MKT: IG), a New Jersey based generic topical pharmaceutical company, today announced it has received its first approval from the U.S. Food and Drug Administration (FDA) for an abbreviated new drug application (ANDA). The FDA has approved IGI's application for lidocaine hydrochloride USP 4% topical solution.
One Reason Why CEL-SCI Has Become One Of 2014's Top Percentage Gainers
ACCESSWIRE - Wed Mar 12, 8:36AM CDT
Los Angeles / March 12, 2014 / Shares of CEL-SCI Corporation (NYSEMKT:CVM), have risen nearly 150% since last December, thus placing them firmly alongside other Pharmaceuticals & Biotechnology stocks like Intercept Pharmaceuticals Inc (NASDAQ:ICPT), Rosetta Genomics Ltd. (NASDAQ GS) and IGI Laboratories, Inc. (NYSEMKT:IG) on the list of early 2014's Top Healthcare Percentage Gainers.
IGI, Laboratories, Inc. (IG) in Focus: Stock up 11.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Mar 11, 7:44AM CDT
IGI, Laboratories, Inc. was a big mover last session, as the company saw its shares surge nearly 12% on the day.
IGI Laboratories To Present At 26th Annual ROTH Capital Conference On March 10, 2014
PR Newswire - Wed Mar 05, 3:05PM CST
IGI Laboratories, Inc. (NYSE Amex: IG), a New Jersey based topical generic pharmaceutical company, will be presenting at the 26th Annual ROTH Conference. The Conference will take place on March 9-12, 2014 at the Ritz-Carlton in Dana Point, California.
IGI Laboratories files 14th ANDA with the US FDA
M2 - Tue Mar 04, 3:56AM CST
US-based topical pharmaceutical company IGI Laboratories (NYSE MKT:IG) revealed on Monday the submission of its first abbreviated new drug application (ANDA) in 2014 to the US Food and Drug Administration (FDA), bringing its total number of ANDA submissions to 14.
IGI Laboratories, Inc. Announces Fourteenth ANDA Submission
PR Newswire - Mon Mar 03, 3:05PM CST
IGI Laboratories, Inc. (NYSE MKT: IG), a New Jersey based generic topical pharmaceutical company, today announced it has submitted its first abbreviated new drug application (ANDA) in 2014 to the U.S. Food and Drug Administration (FDA), which brings the Company's total number of ANDA submissions to fourteen.
IGI Laboratories' net loss narrows to USD0.1m in 2013
M2 - Fri Feb 28, 3:00AM CST
Generic drug company IGI Laboratories (NYSE MKT:IG) revealed on Thursday its net loss of USD0.1m for the year ended 31 December 2013.
IGI Laboratories Announces Fourth Quarter and Year End 2013 Results
PR Newswire - Thu Feb 27, 3:05PM CST
IGI Laboratories, Inc. (NYSE MKT: IG), a New Jersey based topical generic drug development and manufacturing company, announced its financial results for the fourth quarter and year ended December 31, 2013.
IGI Laboratories To Hold Conference Call For 4th Quarter 2013 Results
PR Newswire - Fri Feb 14, 3:15PM CST
IGI Laboratories, Inc. (NYSE MKT: IG), a New Jersey based topical generic drug development and manufacturing company, announced the Company will hold a conference call at 4:30 pm ET on Thursday, February 27, 2014 to discuss the 4th quarter 2013 results.
IGI, Laboratories (IG) Soars: Stock Adds 10.4% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jan 14, 7:57AM CST
IGI, Laboratories, Inc. (IG) was a big mover last session, as the company saw its shares rise over 10% on the day.
IGI Laboratories, Inc. Completes Its Sixth ANDA Filing For 2013 Under Joint Drug Development And Commercialization Agreement
PR Newswire - Tue Dec 31, 12:14PM CST
IGI Laboratories, Inc. (NYSE MKT: IG), a New Jersey based generic topical pharmaceutical company, today announced it executed a license, development, supply and marketing agreement with a large multi-national pharmaceutical company. In accordance with the confidentiality agreement in place, the name of the company remains undisclosed. The agreement designates IGI Laboratories, Inc. (IGI) as the developer and manufacturer of a generic topical pharmaceutical drug product, which will be licensed, marketed and distributed in the United States by our partner, or its subsidiaries. The named product in the agreement was developed at IGI. IGI has now filed the Abbreviated New Drug Application associated with the named generic pharmaceutical product. In accordance with the agreement, our partner is required to pay IGI when certain milestones are met related to the filing and approval of the associated ANDA. In addition, in accordance with the agreement, IGI will also receive a share of the profits following the approval and commercialization of the product.
IGI Laboratories (IG) in Focus: Stock Surges 14.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Nov 15, 7:32AM CST
IGI Laboratories was a big mover in the last session, as the company saw its shares rise over 14% on the day.
IGI Laboratories To Present At Oppenheimer 24th Annual Healthcare Conference On December 10, 2013
PR Newswire - Wed Nov 13, 7:00AM CST
IGI Laboratories, Inc. (NYSE Amex: IG), a New Jersey based generic topical pharmaceutical company will be presenting at the Oppenheimer 24th Annual Healthcare Conference. The Conference will take place on December 10 - 11, 2013 at the Crowne Plaza Hotel in New York, New York.
Can the Rally in IGI Laboratories, Inc. (IG) Shares Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 05, 6:17AM CST
Can the Rally in IGI Laboratories, Inc. (IG) Shares Continue?
IGI Laboratories Inc granted US FDA's formal approval for site transfer of econazole nitrate
M2 - Mon Nov 04, 6:45AM CST
Pharmaceutical company IGI Laboratories Inc (NYSE MKT:IG) reported on Friday the receipt of formal approval of its supplemental filing for the site transfer of econazole nitrate cream 1% to its manufacturing facility in Buena, NJ.
5 Stocks Under $10 to Trade for Breakouts
at The Street - Fri Nov 01, 8:06AM CDT
IGI Laboratories, Inc. Appoints Damian Finio to Board of Directors
PR Newswire - Wed Apr 02, 8:00AM CDT
IGI Laboratories, Inc. (NYSE MKT: IG), a New Jersey-based generic topical pharmaceutical company, today announced that it has appointed Damian Finio to its Board of Directors. Mr. Finio will serve as the new Chairman of the Company's Audit Committee. The Company had announced on March 31, 2014, that Michael Hemric, a Director of the Company has resigned effective April 1, 2014, and Joyce Erony, the Company's chairperson and director, had decided not to run for re-election at the Company's annual meeting on May 27, 2014.
IGI Laboratories To Present At Needham & Company's 13th Annual Healthcare Conference On April 8, 2014
PR Newswire - Mon Mar 31, 7:00AM CDT
IGI Laboratories, Inc. (NYSE Amex: IG), a New Jersey based topical generic pharmaceutical company, will be presenting at the Needham & Company's 13th Annual Healthcare Conference. The Conference will take place on April 8-9, 2014 at the Westin Grand Central Hotel in New York City.
IGI Laboratories (IG) Catches Eye: Stock Up 10.0% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 19, 8:25AM CDT
IGI Laboratories was a big mover last session, with shares rising almost 10% on the day.
IGI Laboratories wins first ANDA approval for lidocaine hydrochloride USP 4% topical solution
M2 - Thu Mar 13, 4:06AM CDT
Pharmaceutical company IGI Laboratories (NYSE MKT:IG) said on Wednesday that it has received the US Food and Drug Administration's (FDA) approval for the abbreviated new drug application (ANDA) of lidocaine hydrochloride USP 4% topical solution.
IGI Laboratories, Inc. Announces First ANDA Approval
PR Newswire - Wed Mar 12, 11:08AM CDT
IGI Laboratories, Inc. (NYSE MKT: IG), a New Jersey based generic topical pharmaceutical company, today announced it has received its first approval from the U.S. Food and Drug Administration (FDA) for an abbreviated new drug application (ANDA). The FDA has approved IGI's application for lidocaine hydrochloride USP 4% topical solution.
One Reason Why CEL-SCI Has Become One Of 2014's Top Percentage Gainers
ACCESSWIRE - Wed Mar 12, 8:36AM CDT
Los Angeles / March 12, 2014 / Shares of CEL-SCI Corporation (NYSEMKT:CVM), have risen nearly 150% since last December, thus placing them firmly alongside other Pharmaceuticals & Biotechnology stocks like Intercept Pharmaceuticals Inc (NASDAQ:ICPT), Rosetta Genomics Ltd. (NASDAQ GS) and IGI Laboratories, Inc. (NYSEMKT:IG) on the list of early 2014's Top Healthcare Percentage Gainers.
IGI, Laboratories, Inc. (IG) in Focus: Stock up 11.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Mar 11, 7:44AM CDT
IGI, Laboratories, Inc. was a big mover last session, as the company saw its shares surge nearly 12% on the day.
IGI Laboratories To Present At 26th Annual ROTH Capital Conference On March 10, 2014
PR Newswire - Wed Mar 05, 3:05PM CST
IGI Laboratories, Inc. (NYSE Amex: IG), a New Jersey based topical generic pharmaceutical company, will be presenting at the 26th Annual ROTH Conference. The Conference will take place on March 9-12, 2014 at the Ritz-Carlton in Dana Point, California.
IGI Laboratories files 14th ANDA with the US FDA
M2 - Tue Mar 04, 3:56AM CST
US-based topical pharmaceutical company IGI Laboratories (NYSE MKT:IG) revealed on Monday the submission of its first abbreviated new drug application (ANDA) in 2014 to the US Food and Drug Administration (FDA), bringing its total number of ANDA submissions to 14.
IGI Laboratories, Inc. Announces Fourteenth ANDA Submission
PR Newswire - Mon Mar 03, 3:05PM CST
IGI Laboratories, Inc. (NYSE MKT: IG), a New Jersey based generic topical pharmaceutical company, today announced it has submitted its first abbreviated new drug application (ANDA) in 2014 to the U.S. Food and Drug Administration (FDA), which brings the Company's total number of ANDA submissions to fourteen.
IGI Laboratories' net loss narrows to USD0.1m in 2013
M2 - Fri Feb 28, 3:00AM CST
Generic drug company IGI Laboratories (NYSE MKT:IG) revealed on Thursday its net loss of USD0.1m for the year ended 31 December 2013.
IGI Laboratories Announces Fourth Quarter and Year End 2013 Results
PR Newswire - Thu Feb 27, 3:05PM CST
IGI Laboratories, Inc. (NYSE MKT: IG), a New Jersey based topical generic drug development and manufacturing company, announced its financial results for the fourth quarter and year ended December 31, 2013.
IGI Laboratories To Hold Conference Call For 4th Quarter 2013 Results
PR Newswire - Fri Feb 14, 3:15PM CST
IGI Laboratories, Inc. (NYSE MKT: IG), a New Jersey based topical generic drug development and manufacturing company, announced the Company will hold a conference call at 4:30 pm ET on Thursday, February 27, 2014 to discuss the 4th quarter 2013 results.
IGI, Laboratories (IG) Soars: Stock Adds 10.4% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jan 14, 7:57AM CST
IGI, Laboratories, Inc. (IG) was a big mover last session, as the company saw its shares rise over 10% on the day.
IGI Laboratories, Inc. Completes Its Sixth ANDA Filing For 2013 Under Joint Drug Development And Commercialization Agreement
PR Newswire - Tue Dec 31, 12:14PM CST
IGI Laboratories, Inc. (NYSE MKT: IG), a New Jersey based generic topical pharmaceutical company, today announced it executed a license, development, supply and marketing agreement with a large multi-national pharmaceutical company. In accordance with the confidentiality agreement in place, the name of the company remains undisclosed. The agreement designates IGI Laboratories, Inc. (IGI) as the developer and manufacturer of a generic topical pharmaceutical drug product, which will be licensed, marketed and distributed in the United States by our partner, or its subsidiaries. The named product in the agreement was developed at IGI. IGI has now filed the Abbreviated New Drug Application associated with the named generic pharmaceutical product. In accordance with the agreement, our partner is required to pay IGI when certain milestones are met related to the filing and approval of the associated ANDA. In addition, in accordance with the agreement, IGI will also receive a share of the profits following the approval and commercialization of the product.
IGI Laboratories (IG) in Focus: Stock Surges 14.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Nov 15, 7:32AM CST
IGI Laboratories was a big mover in the last session, as the company saw its shares rise over 14% on the day.
IGI Laboratories To Present At Oppenheimer 24th Annual Healthcare Conference On December 10, 2013
PR Newswire - Wed Nov 13, 7:00AM CST
IGI Laboratories, Inc. (NYSE Amex: IG), a New Jersey based generic topical pharmaceutical company will be presenting at the Oppenheimer 24th Annual Healthcare Conference. The Conference will take place on December 10 - 11, 2013 at the Crowne Plaza Hotel in New York, New York.
Can the Rally in IGI Laboratories, Inc. (IG) Shares Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 05, 6:17AM CST
Can the Rally in IGI Laboratories, Inc. (IG) Shares Continue?
IGI Laboratories Inc granted US FDA's formal approval for site transfer of econazole nitrate
M2 - Mon Nov 04, 6:45AM CST
Pharmaceutical company IGI Laboratories Inc (NYSE MKT:IG) reported on Friday the receipt of formal approval of its supplemental filing for the site transfer of econazole nitrate cream 1% to its manufacturing facility in Buena, NJ.
5 Stocks Under $10 to Trade for Breakouts
at The Street - Fri Nov 01, 8:06AM CDT
